Biolase Appoints Biotechnology Entrepreneur to its Board of Directors

BIOLASE Inc., the global leader in dental lasers, has appointed Richard B. Lanman, M.D., a well-known biotechnology entrepreneur who specializes in accelerating the development and adoption of novel medical technologies, to its Board of Directors, effective Nov. 1. The appointment of Lanman replaces outgoing director Fredrick H. Moll, M.D., who resigned from the board due to his commitments associated with his role as CEO of Auris Surgical Robotics Inc.
 
Lanman, 62, is a board-certified neurologist and physiatrist currently serving as the chief medical officer at Guardant Health Inc. During his career, he has also served on a number of Boards of Directors and Advisory Boards and he has authored 45 articles that have been published in peer reviewed scientific journals.
 
“His extensive board and executive management experience and his focus on developing and commercializing disruptive medical technologies and procedures make Dr. Lanman a terrific addition to our board,” said Johnathan T. Lord, M.D., BIOLASE board chairman. “We look forward to his advice and counsel as our board, together with President and CEO Harold Flynn and his executive management team, continue to concentrate on establishing BIOLASE and its innovative dental laser systems as the standard of care in dentistry. I would also like to thank Dr. Moll for his many years of valuable service to BIOLASE and wish him the very best.”
 
Lanman joined Guardant Health in September 2014 and as its chief medical officer, he has planned and executed the clinical and analytical validity, and clinical utility studies to bring novel cell-free DNA next generation sequencing technology to widespread adoption.
 
From July 2008 until September 2014 Lanman was with Veracyte Inc., where he drove the validation and clinical utility studies required to commercialize genomic diagnostics in thyroid and lung neoplasia that facilitate improved diagnosis utilizing small, minimally-invasive biopsies. Veracyte went public in 2013. He also previously served as chief medical officer for two cardiovascular biodiagnostic companies, diaDexus and Atherotech, and prior to that, Lanman was the medical director and senior vice president of San Jose Medical Group and a chief of quality at Kaiser Permanente.
 
Lanman completed his internship and residency at the University of California San Francisco, after receiving his medical degree from Northwestern University and a bachelor of science degree in chemistry from Stanford University, where he graduated Phi Beta Kappa.
 
BIOLASE develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including cone beam digital X-rays and CAD/CAM intra-oral scanners. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 210 patented and 90 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 34,900 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.